Safe Use of Systemic Interferons for Multiple Sclerosis Treatment


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Тек жазылушылар үшін

Аннотация

The safety of interferons was assessed by analyzing 499 spontaneous reports in the Russian database from 2015 to 2017. The results led to the conclusion that the safety profile of systemic interferon preparations that are widely used in medical practice to treat multiple sclerosis is defined by data in spontaneous reports for the development of adverse reactions to them or the ineffectiveness of using them.

Авторлар туралы

I. Snegireva

Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Хат алмасуға жауапты Автор.
Email: SnegirevaII@expmed.ru
Ресей, 8/2 Petrovskii Blvd, Moscow, 127051

M. Darmostukova

Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Email: SnegirevaII@expmed.ru
Ресей, 8/2 Petrovskii Blvd, Moscow, 127051

A. Kazakov

Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Email: SnegirevaII@expmed.ru
Ресей, 8/2 Petrovskii Blvd, Moscow, 127051

V. Lepakhin

Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Email: SnegirevaII@expmed.ru
Ресей, 8/2 Petrovskii Blvd, Moscow, 127051

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML

© Springer Science+Business Media, LLC, part of Springer Nature, 2019